美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Militia Long/Short Equity ETF

31.64

+0.11880.38%

盤後：31.63-0.0088-0.03%16:04 EDT

成交量：10.81萬

成交額：342.65萬

市值：1.38億

市盈率：- -

高：31.85

開：31.74

低：31.61

收：31.52

52周最高：32.87

52周最低：25.63

股本：436.00萬

流通股本：431.00萬

量比：2.38

換手率：2.51%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

安科生物披露創新藥HuA21注射液在2025年歐洲腫瘤內科學會年會公佈臨牀研究數據

FAK賽道處於爆發前夜！應世生物深耕佈局，全球領跑

藥明巨諾：國產病毒載體版倍諾達補充申請獲國家藥監局受理

創新藥尋突圍，「自研+引入」雙軌戰略能否重塑增長極？

21世纪经济报道

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":31.6388,"timestamp":1761249600000,"preClose":31.52,"halted":0,"volume":108136,"hourTrading":{"tag":"盘后","latestPrice":31.63,"preClose":31.6388,"latestTime":"16:04 EDT","volume":1,"amount":31.63,"timestamp":1761249851524},"delay":0,"floatShares":4310000,"shares":4360000,"eps":0,"marketStatus":"盤後交易","change":0.1188,"latestTime":"10-23 19:59:50 EDT","open":31.74,"high":31.8485,"low":31.61,"amount":3426477.35722,"amplitude":0.007567,"askPrice":47.47,"askSize":200,"bidPrice":31,"bidSize":80,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1761264000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":31.52,"sharesOutstanding":4360000,"nav":31.65,"aum":137994000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.63,"preClose":31.6388,"latestTime":"16:04 EDT","volume":1,"amount":31.63,"timestamp":1761249851524},"volumeRatio":2.382994},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":4310000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.382994,"shares":4360000,"dividePrice":0,"high":31.8485,"amplitude":0.007567,"preClose":31.52,"low":31.61,"week52Low":25.63,"pbRate":"--","week52High":32.87,"institutionHeld":0,"latestPrice":31.6388,"committee":-0.428571,"eps":0,"divideRate":0,"volume":108136,"delay":0,"ttmEps":0,"open":31.74,"prevYearClose":25.88,"prevWeekClose":31.18,"prevMonthClose":31.475,"prevQuarterClose":31.475,"fiveDayClose":30.9996,"twentyDayClose":32.0026,"sixtyDayClose":29.9947},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577639389","title":"安科生物披露創新藥HuA21注射液在2025年歐洲腫瘤內科學會年會公佈臨牀研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2577639389","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577639389?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 08:53","pubTimestamp":1761007995,"startTime":"0","endTime":"0","summary":"格隆汇10月21日丨安科生物公布，公司于2025年10 月 17 日至 21 日在德国柏林召开的欧洲肿瘤内科学会年会上，以壁报形式公布自主研发的生物创新药重组抗 HER2 人源化HuA21 单克隆抗体注射液联合曲妥珠单抗和化疗治疗HER2 阳性晚期胃/胃食管交界处腺癌 Ib/II 期剂量递增和扩展研究的最新研究成果。HuA21 通过诱导 HER2 受体的内吞和下调，打断癌细胞信号通路，从而抑制癌细胞生长和增殖，产生促进癌细胞凋亡、抗肿瘤血管生成等效果，最终达到抑制肿瘤的作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","BK4181","PK","KG","BK4218","BK4019"],"gpt_icon":0},{"id":"2575701254","title":"FAK賽道處於爆發前夜！應世生物深耕佈局，全球領跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2575701254","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575701254?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 12:29","pubTimestamp":1760416190,"startTime":"0","endTime":"0","summary":"协同管线布局，拓展治疗边界为巩固赛道领先地位，应世生物还布局了第二代选择性FAK抑制剂IN10028，依托ifebemtinib的研发经验，优化与RAS抑制剂、ADC等疗法的协同效果，计划于2025年第四季度提交IND申请，2026年启动首次人体临床试验。Ifebemtinib有望成为同类最佳的选择性FAK抑制剂，凭借ifebemtinib的先发优势与协同管线布局，应世生物有望在这一蓝海市场中占据领先地位。截至2025年3月末，公司账上的现金及","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1760316553550547598","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4563","BK4509","BK4171","BK4108","BK4007","TME","BK4224","BK4585","LU0456842615.SGD","LU2039709279.SGD","BK4588","BK4565","IE00BYQNZ168.SGD","PLD","BK4535","PROC","BK4526","LU0359201612.USD","BK4531","BK4548","BK4534","IE00B12V2V27.USD","LU0359202008.SGD","IE00BYTNYN87.SGD","ORR","01698","SG9999011746.SGD","BK4552","BK4571","BK4567","LU1023057109.AUD"],"gpt_icon":0},{"id":"2574538681","title":"藥明巨諾：國產病毒載體版倍諾達補充申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2574538681","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574538681?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 17:48","pubTimestamp":1760003334,"startTime":"0","endTime":"0","summary":"10月9日，药明巨诺（02126）发布公告，中国国家药品监督管理局已正式受理公司倍诺达?使用国产病毒载体的上市后补充申请。此次申请基于一项II期单臂研究，旨在评估使用新工艺病毒载体（JWLV011）生产的瑞基奥仑赛注射液与现有病毒载体生产的产品可比性。研究结果显示，3个月最佳客观缓解率（ORR）为66.67%，疾病完全缓解率（CR）为41.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510093529591131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4161","CR","ORR"],"gpt_icon":0},{"id":"2570035010","title":"創新藥尋突圍，「自研+引入」雙軌戰略能否重塑增長極？","url":"https://stock-news.laohu8.com/highlight/detail?id=2570035010","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570035010?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 12:59","pubTimestamp":1758862756,"startTime":"0","endTime":"0","summary":"与此同时，2025年第二季度中国创新药对外BD首付款金额高达17.3亿美元，远超同期中国生物医药投融资金额6.9亿美元。根据药智网公布的数据，创新药从临床试验Ⅰ期到批准上市的可能性为12.69%，而整体研发成功率则更低。BD合作已成为创新药研发投入的新资金来源和主要资金来源。柳丹指出，未盈利创新药企需多元融资保障生存。今年上半年全球医药交易TOP10中，中国创新药资产的贡献率超过80%，且交易金额最高的资产也来自国内药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LEGN","BK4505","BK4588","ORR","BK4585","BK4139","02142"],"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}